Enclomiphene Research Guide

What Is Enclomiphene?

Enclomiphene (also called trans-clomiphene or androxal) is the (E)-isomer of clomiphene citrate. It is classified as a selective estrogen receptor modulator (SERM) — meaning it acts as an estrogen receptor antagonist in some tissues (hypothalamus, pituitary) while potentially acting as an agonist in others.

It was developed by Repros Therapeutics specifically to treat secondary hypogonadism (low testosterone resulting from hypothalamic/pituitary dysfunction rather than primary testicular failure). The novel aspect of enclomiphene vs standard testosterone replacement therapy (TRT) is that it stimulates endogenous testosterone production rather than suppressing it.

Enclomiphene is an investigational compound. It has no approved therapeutic indication. All supply is For Research Use Only.

SERM Mechanism: Hypothalamic ER Antagonism

The hypothalamic-pituitary-gonadal (HPG) axis is regulated by feedback loops involving testosterone and estradiol (estrogen). Estradiol — produced by aromatization of testosterone — exerts strong negative feedback at the hypothalamus and pituitary:

• Hypothalamus: Estradiol suppresses GnRH pulse frequency and amplitude
• Pituitary: Estradiol suppresses LH and FSH secretion from gonadotrophs

Enclomiphene blocks estrogen receptors (ERα primarily) at the hypothalamus and pituitary, removing this estrogen-mediated brake on the HPG axis:

• ↑ GnRH pulse frequency → ↑ LH/FSH → ↑ testicular testosterone production
• Endogenous testosterone pathway is preserved (no exogenous testosterone)
• Testicular function (spermatogenesis, Sertoli cell function) is maintained or enhanced

Enclomiphene vs Clomiphene (Clomid)

Clomiphene citrate (Clomid) is a 1:1 racemic mixture of enclomiphene (trans) and zuclomiphene (cis). The critical pharmacological difference:

The rationale for isolated enclomiphene: removing zuclomiphene eliminates accumulating partial ER agonism that may contribute to clomiphene's reported side effects (visual disturbances, mood changes, hot flushes) from long-term or repeated-cycle use.

HPTA Axis Stimulation

The research-relevant HPTA effects of enclomiphene documented across clinical and preclinical studies:

• LH increase: 2–4× baseline LH elevation within 24–48 hours of first dose at 25 mg/day
• Testosterone restoration: Serum testosterone increases from hypogonadal levels (<300 ng/dL) to eugonadal range (400–700 ng/dL) within 2–4 weeks at therapeutic doses
• Testicular volume: Preserved or increased (vs decreased with TRT)
• Spermatogenesis: Maintained — relevant for fertility research contexts; TRT suppresses spermatogenesis

Phase III Clinical Data

Repros Therapeutics conducted two Phase III trials for enclomiphene in secondary hypogonadism:

• ZA-204: 12-week RCT, enclomiphene 12.5mg or 25mg vs testosterone gel (Androgel 1.62%) vs placebo in men with secondary hypogonadism (low T + elevated LH/FSH excluded). Primary endpoint: testosterone normalization. Enclomiphene 25mg achieved testosterone normalization in 83% vs 76% for T-gel, with maintenance of spermatogenesis (vs suppression with T-gel).
• ZA-301: 16-week RCT extending safety and efficacy data. Confirmed testosterone normalization, LH/FSH elevation, and favorable metabolic profile vs testosterone gel.
• FDA CRL (2016): Complete Response Letter from FDA requested cardiovascular safety data — standard for hormonal therapies post-TRT cardiovascular controversy. Development rights transferred to Androvia Biosciences after Repros.

Enclomiphene vs TRT in Research Context

For fertility-preserving testosterone restoration research, enclomiphene's HPTA-stimulating approach is the key differentiator vs exogenous testosterone.